This September, Atogepant (QUILIPTA) received approval by the FDA for the preventive treatment of episodic migraine in adults. Atogepant is the first and only oral calcitonin gene-related peptide (CGRP) receptor antagonist. CGRP and its receptors are exhibited in regions of the nervous system associated with migraine physiopathology. Atogepant blocks CGRP within a one dose per day.

It contains 2-aminopiperidin-3-one moiety in its backbone.


We have made a set of Building Blocks, which contain such parts – the perfect start for your research!